Echocardiography

HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients

Retrieved on: 
星期二, 三月 26, 2024
Diabetes, Disease, Echocardiography, HSCS, Congress, Algorithm, Intelligence, Anesthesia, Patient, Mortality, LVDD, Society, Anesthesiology, Type, Use, American Society of Echocardiography, Medical device

Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.

Key Points: 
  • Preoperative left ventricular diastolic dysfunction (LVDD) is very common and one of the important causes of perioperative morbidity and mortality in cardiac and non-cardiac surgeries.
  • In the study, patients undergoing preoperative anesthesia evaluation for cardiac and non-cardiac surgeries were enrolled.
  • For patients indicated for preoperative echocardiography, LVDD was diagnosed and graded as per American Society of Echocardiography (ASE) guidelines and a MyoVista wavECG was also performed.
  • Based on these findings, 25 of the 60 non-LVDD patients could be safely excluded from referral to preoperative echocardiography.

Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure

Retrieved on: 
星期二, 三月 26, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Other Health, GPCR, Disease, Harvard Medical School, Echocardiography, Cardiovascular disease, Pulmonary hypertension, Patient, Mortality, Tectonics, MD, Biology, Safety, Pharmacology, Relaxin, Heart failure, Pharmaceutical industry

The study will evaluate the safety and hemodynamic effects of single-dose TX45 in patients with Group 2 Pulmonary Hypertension secondary to Heart Failure with preserved Ejection Fraction (Group 2 PH with HFpEF).

Key Points: 
  • The study will evaluate the safety and hemodynamic effects of single-dose TX45 in patients with Group 2 Pulmonary Hypertension secondary to Heart Failure with preserved Ejection Fraction (Group 2 PH with HFpEF).
  • Group 2 PH with HFpEF impacts over 600,000 patients in the US and is associated with significant morbidity and mortality.
  • The Phase 1B study with TX45 in patients with Group 2 PH with HFpEF is a single dose, open-label study to evaluate safety, tolerability and acute hemodynamic effects of intravenous administration of TX45.
  • The study will evaluate the effect of TX45 on hemodynamic parameters, as determined by right heart catheterization and echocardiography.

ICUS Endorses Expanded Role of Sonographers in CEUS Procedures

Retrieved on: 
星期四, 三月 21, 2024
Other Health, Other Science, Pharmaceutical, Other Technology, Research, Oncology, Medical Devices, Hospitals, Genetics, Stem Cells, Science, Technology, Nursing, Cardiology, General Health, Biotechnology, Health, Health Technology, Diagnosis, Radiation, Brain, Organization, Contrast-enhanced ultrasound, UEA, IPhone, Thomas Jefferson University, CEUS, Diagnostic medical sonography, SDMS, Risk, Patient, ICUS, Echocardiography, Society, GE HealthCare, CME, Scope of practice, Google Images, Agent handling, Kidney, Definity, Android, Accreditation, Medical imaging

More patients will now have access to safe and inexpensive diagnostic scans known as “contrast-enhanced ultrasound” (CEUS) as a result of the expanding role of sonographers, according to the International Contrast Ultrasound Society (ICUS).

Key Points: 
  • More patients will now have access to safe and inexpensive diagnostic scans known as “contrast-enhanced ultrasound” (CEUS) as a result of the expanding role of sonographers, according to the International Contrast Ultrasound Society (ICUS).
  • “Sonographers play a vital role in conducting CEUS examinations, and continually learning new techniques, such as CEUS, is a core component of providing innovative care and elevating our profession,” said Maria Stanczak, a member of the ICUS board of directors who played a key role in updating CEUS content in the new Scope of Practice.
  • ICUS does not charge fees for membership, CME-accredited webinars on CEUS, newsletters and other CEUS resources or programming.
  • To join ICUS, register and learn more, visit the ICUS website at www.ICUS-Society.org , or download the free ICUS app for iPhone and Android devices.

Clarius Mobile Health Named to Fast Company's 2024 List of the World's Most Innovative Companies

Retrieved on: 
星期二, 三月 19, 2024
Echocardiography, MIC, Patient, AI, Hope, ITunes, Most, Clarius, Engineering, Medical imaging

VANCOUVER, BC, March 19, 2024 /PRNewswire/ -- Clarius Mobile Health, a global leader in wireless ultrasound solutions, has been named to Fast Company's prestigious annual list of the World's Most Innovative Companies. Clarius earned the #2 standing in the medical device category for its outstanding contributions to improving healthcare with innovation.

Key Points: 
  • Clarius earned the #2 standing in the medical device category for its outstanding contributions to improving healthcare with innovation.
  • "We push the limits of innovation every day at Clarius to improve access to medical imaging for all and it's a great honour to have our efforts recognized by Fast Company," said Clarius CEO Ohad Arazi.
  • Fast Company's Most Innovative Companies package is available online , as well as in-app via iTunes, and on newsstands beginning March 26.
  • "Our list of the Most Innovative Companies is both a comprehensive look at the innovation economy and a snapshot of the business trends that defined the year," said Fast Company editor-in-chief Brendan Vaughan.

HeartSciences Adds Key Advisor to its Scientific Advisory Board

Retrieved on: 
星期一, 二月 26, 2024
Sengupta, HSCS, Rutgers University, Division, AI, Intelligence, Cardiac imaging, Education, Teaching, Echocardiography, University School, Editor-in-chief, ECG, American Medical Association, Society, Heart failure, Lung, TEDMED, European Society of Cardiology, Journal, FACC, MBBS, Publication, Holography, Research, Medical device

Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.

Key Points: 
  • Sengupta has been an author on multiple peer reviewed AI-ECG publications using the Company’s technology and we are delighted to have someone of his caliber join our growing Scientific Advisory Board,” said Andrew Simpson, CEO of HeartSciences.
  • He served on the Board of Directors for the American Society of Echocardiography (ASE) and as the Chair of the ASE Telehealth and New Technology Taskforce.
  • In 2020, Dr. Sengupta was named a Richard Popp Excellence in Teaching Award recipient by the American Society of Echocardiography.
  • I look forward to helping HeartSciences further advance the field of AI in cardiology.”

4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024

Retrieved on: 
星期一, 二月 12, 2024
C102, Atypical hemolytic uremic syndrome, Fabry disease, CPET, VO2, FDA, Quality of life, Cardiovascular disease, Data, GLS, Safety, MCID, Overalls, Death, Patient, Echocardiography, Chelsea Handler, Pharmaceutical industry

The data was presented in a late-breaking session at WORLDSymposium™ 2024 in San Diego, California on Friday, February 9, 2024.

Key Points: 
  • The data was presented in a late-breaking session at WORLDSymposium™ 2024 in San Diego, California on Friday, February 9, 2024.
  • “We are pleased to see 4D-310 continue to consistently demonstrate clinical activity across multiple important cardiac endpoints including cardiac function, exercise capacity and quality of life,” said Robert Kim, M.D., Chief Medical Officer of 4DMT.
  • “Current therapies do not adequately address Fabry-related cardiovascular manifestations, and cardiovascular disease is the most common cause of death in these patients.
  • “No approved therapy has been shown to definitively clear accumulated Gb3 from cardiomyocytes in patients with Fabry disease, which speaks to 4D-310’s highly differentiated profile.

New Philips Mini TEE ultrasound transducer helps improve cardiac care for more patients

Retrieved on: 
星期三, 一月 31, 2024
ICU, Surgeon, PHG, Workflow, Heart, Ventricular septal defect, AI, Catheter, 3D, Patient, Twilight anesthesia, Diagnosis, TEE, FDA, Columbia University, Mini, Echocardiography, Society, Physician, Risk, Cardiology, AEX, Detection, EPIQ, Medical imaging

Cardiovascular ultrasound has played a key role in the evolution of early diagnosis of structural heart disease, led by a technology pioneered by Philips: the ‘transesophageal echocardiography’ (TEE) ultrasound transducer.

Key Points: 
  • Cardiovascular ultrasound has played a key role in the evolution of early diagnosis of structural heart disease, led by a technology pioneered by Philips: the ‘transesophageal echocardiography’ (TEE) ultrasound transducer.
  • Announced today, Philips’ new X11-4t Mini 3D TEE transducer is shifting that balance and opening 3D TEE imaging to previously unaddressed patients [5].
  • “As a pioneer and leading innovator in cardiac ultrasound, our 3D ultrasound technology plays a critical role in many cardiac procedures.
  • The Philips X11-4t ultrasound transducer is scheduled for commercial availability in 2024 and is pending CE mark in Europe.

First Coast Cardiovascular Institute and CardioHealth Partner to Advance Cardiovascular Care for Northeast Florida Residents

Retrieved on: 
星期一, 一月 29, 2024
Electrophysiology, Valvular heart disease, Patient, Cardiology, Hypertension, Trust, Health, Partnership, Atrial fibrillation, History, Echocardiography, FACC, FCCI, Amputation, Heart, Cardiovascular disease

JACKSONVILLE, Fla., Jan. 29, 2024 /PRNewswire-PRWeb/ -- First Coast Cardiovascular Institute, a Cardiovascular Logistics partner practice that offers cardiovascular medicine, sleep medicine, pulmonology, and amputation prevention to residents in Northeast Florida and Southern Georgia, has joined forces with CardioHealth, a Jacksonville-based cardiovascular practice that specializes in delivering exceptional care to patients with hypertension, congestive heart failure, atrial fibrillation, and valvular heart disease. Together, they aim to advance cardiovascular care across Northeast Florida.

Key Points: 
  • Together, they aim to advance cardiovascular care across Northeast Florida.
  • "We are thrilled to partner with CardioHealth to provide the highest quality cardiovascular care to Northeast Florida patients," said Dr. Khatib, President of FCCI.
  • "We are thrilled to partner with CardioHealth to provide the highest quality cardiovascular care to Northeast Florida patients," said Dr. Khatib, President of FCCI.
  • "This collaboration between First Coast Cardiovascular Institute and CardioHealth marks a significant milestone for both practices," said David Konur, CEO of Cardiovascular Logistics.

Sensydia Completes Fifth Study for Heart-Sound AI

Retrieved on: 
星期二, 一月 16, 2024
Cardiology, University, Biotechnology, Education, Technology, Health, Medical Devices, Research, Artificial Intelligence, Science, Clinical Trials, Knowledge, Artificial intelligence, Patient, Associate, MD, Life, Multimedia, Cardiac output, Heart failure, Echocardiography, Algorithm, Principal investigator, University of Minnesota, NIH, FDA, UMN, CPS, Ronald Reagan, Diagnosis, Pulmonary hypertension, Medical device

Non-invasive cardiac assessment company Sensydia announced today that it has completed its 50-subject development study at the University of Minnesota (UMN).

Key Points: 
  • Non-invasive cardiac assessment company Sensydia announced today that it has completed its 50-subject development study at the University of Minnesota (UMN).
  • In January 2022, Sensydia announced that CPS was granted Breakthrough Device Designation by the United States Food and Drug Administration (FDA).
  • Sensydia plans to use data from this 50-subject study to develop the CPS pulmonary pressure algorithms.
  • The achievement of this 50-subject milestone comes at a time when Sensydia is actively executing Phase I of its new NIH award.

Global Cardiac Bio Implant Devices Market Size and Forecast Report 2023: A $60+ Billion Industry by 2030 - Growing Attractiveness of Bio-implant Treatments Bolsters Growth - ResearchAndMarkets.com

Retrieved on: 
星期一, 一月 15, 2024
Biotechnology, Health, Cardiology, Medical Devices, Ageing, Diabetes, Obesity, Moyamoya disease, American Heart Association, Woman, Arthroscopy, Beauty, Binge drinking, Incidence, Cardiac catheterization, CRT, Angiography, Smoking, Application, Heart failure, Element, Echocardiography, ISR, USD, Cardiac resynchronization therapy, IHD, Diagnosis, Prevalence, Medical device

The "Cardiac Bio Implant Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cardiac Bio Implant Devices Market, Size, Global Forecast 2023-2030, Industry Trends, Growth, Share, Outlook, Impact of Inflation, Opportunity Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Global Cardiac Bio-Implants Device Market size is estimated to be US$ 60.20 Billion by 2030.
  • The global cardiac bio-implants market changed into worth USD 34.70 Billion in 2022.
  • The growth of the Cardiac Catheterization laboratory market is primarily fueled by the increasing prevalence of cardiovascular disorders and advancements in Cardiac Catheterization lab technology.